Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.95
- Piotroski Score 6.00
- Grade Neutral
- Symbol (GSK)
- Company GSK plc
- Price $36.66
- Changes Percentage (2.12%)
- Change $0.76
- Day Low $36.14
- Day High $36.73
- Year High $45.93
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
- Last Earnings 10/30/2024
- Ex-Dividend for 5/16 Dividend 11/15/2024
- Dividend Payable 01/09/2025
- Today N/A
- Next Earnings (Estimated) 01/29/2025
- Fiscal Year End N/A
- Average Stock Price Target $53.00
- High Stock Price Target $85.00
- Low Stock Price Target $36.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $2.78
- Trailing P/E Ratio 14.82
- Forward P/E Ratio 14.82
- P/E Growth 14.82
- Net Income $4.93 B
Income Statement
Quarterly
Annual
Latest News of GSK
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
GSK's RSV vaccine approved in Canada for adults aged 50 to 59
GlaxoSmithKline's AREXVY vaccine has been approved in Canada for adults aged 50-59 to prevent RSV lower respiratory tract disease. The expanded approval follows positive Phase III trial results, with ...
By Yahoo! Finance | 1 day ago -
GSK PLC (GSK) Q3 2024 Earnings Call Highlights: Strong Specialty Medicines Growth Amid Vaccine ...
GSK anticipates profitable growth in 2025, led by Specialty Medicines. Sales of Shingrix in China face challenges, with flexibility in the Zhifei contract. Arexvy sales show promise internationally, w...
By Yahoo! Finance | 1 week ago -
GSK Takes A Header As Vaccine Sales Plummet, Miss
GSK stock plummeted due to declining vaccine sales in Q3. Sales dropped 2% to 8.01 billion pounds, missing analyst estimates. Vaccine sales, notably for Arexvy and Shingrix, fell, but GSK maintains it...
By Investor's Business Daily | 1 week ago
